Maple Capital Management Inc. boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 96,166 shares of the company’s stock after buying an additional 2,270 shares during the period. Eli Lilly and makes up approximately 2.2% of Maple Capital Management Inc.’s holdings, making the stock its 15th biggest holding. Maple Capital Management Inc. owned 8,733.71% of Eli Lilly and worth $8,226,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Eli Lilly and by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after acquiring an additional 1,610,885 shares in the last quarter. BlackRock Inc. grew its stake in shares of Eli Lilly and by 2.1% during the 2nd quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock worth $5,232,942,000 after acquiring an additional 1,323,259 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Eli Lilly and by 7,093.5% during the 2nd quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after acquiring an additional 9,223,251 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Eli Lilly and by 8.4% during the 1st quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock worth $764,597,000 after acquiring an additional 708,597 shares in the last quarter. Finally, Janus Capital Management LLC grew its stake in shares of Eli Lilly and by 2.8% during the 1st quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock worth $733,731,000 after acquiring an additional 237,619 shares in the last quarter. Hedge funds and other institutional investors own 76.42% of the company’s stock.
Eli Lilly and Company (NYSE LLY) traded down $1.39 during trading hours on Friday, hitting $86.50. 4,388,300 shares of the company traded hands, compared to its average volume of 3,686,396. Eli Lilly and Company has a twelve month low of $69.66 and a twelve month high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $96,775.25, a PE ratio of 21.49, a PEG ratio of 1.80 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same period last year, the business earned $0.88 earnings per share. The firm’s revenue was up 9.0% on a year-over-year basis. research analysts predict that Eli Lilly and Company will post 4.21 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a yield of 2.60%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s payout ratio is 98.58%.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the transaction, the insider now directly owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 651,088 shares of company stock valued at $56,439,586. Company insiders own 0.20% of the company’s stock.
LLY has been the subject of several research reports. Jefferies Group reaffirmed a “buy” rating and set a $89.00 price target on shares of Eli Lilly and in a research note on Monday, September 11th. BMO Capital Markets reaffirmed an “underperform” rating and set a $71.00 price target (down from $73.00) on shares of Eli Lilly and in a research note on Wednesday, September 6th. Credit Suisse Group cut shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and raised their price target for the stock from $84.23 to $88.00 in a research note on Tuesday, October 10th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $105.00 price target (up from $103.00) on shares of Eli Lilly and in a research note on Friday, September 8th. Finally, Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research note on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Eli Lilly and presently has an average rating of “Hold” and an average target price of $90.25.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.